readthroughSign in
Jul 21, 2026Weekly roundup

Axsome registers two Phase 3 solriamfetol trials in pediatric and adolescent ADHD

Axsome Therapeutics is recruiting for FOCUS-2 and FOCUS-3, twin Phase 3 studies testing solriamfetol against placebo in children and adolescents with ADHD.

Axsome Therapeutics has two Phase 3 trials of solriamfetol for ADHD recruiting as of the trial registry's last update on 2026-09-08.

  • FOCUS-2 (NCT07717879, SOL-ADHD-302) is testing solriamfetol in children aged 6 to <12 with ADHD. Subjects will be randomized in a 1:1:1 ratio to receive solriamfetol dose A, solriamfetol dose B or placebo once daily for 6 weeks.1 The study is recruiting an estimated 468 participants1 with a primary endpoint of ADHD-RS-5 Total Score, Change from Baseline to Week 6.1
  • FOCUS-3 (NCT07717892, SOL-ADHD-304) tests the same drug in adolescents aged 12 to <18 with ADHD. Subjects will be randomized in a 1:1:1 ratio to receive solriamfetol dose A, solriamfetol dose B or placebo once daily for 6 weeks.2 This trial also aims to enroll 468 participants2, with the same ADHD-RS-5 Total Score, Change from Baseline to Week 62 primary outcome measure.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.